Park Avenue Securities LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 31.4% during the ...

A Texas woman was sentenced Wednesday to one year of probation after she admitted to using fake names to smuggle an unapproved drug from China and Hong Kong into the United to treat a fatal cat ...

Although biotech revenue and R&D spending continued to expand rapidly last year, profitability became a little more elusive. R&D as a share of revenue declined slightly from 34% the previous year ...

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

B2B is often seen to lag behind B2C in marketing, and nowhere is that more true than in the pharmaceuticals industry. Pharma isn’t exactly known for its creativity, and brand-building often ...

MENLO PARK, Calif., Jan. 6, 2025 /PRNewswire/ -- Meta today announced ... Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases Gilead Sciences, Inc. and LEO Pharma today ...

The latest trading session saw Gilead Sciences (GILD) ending at $92.96, denoting a +1.22% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily gain of ...

Jan 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab and the U.S. government have settled a billion-dollar patent ...